Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert MotzerBoris AlekseevSun-Young RhaCamillo PortaMasatoshi EtoThomas PowlesViktor GrünwaldThomas E HutsonEvgeny KopyltsovMaría J Méndez-VidalVadim KozlovAnna AlyasovaSung-Hoo HongAnil KapoorTeresa Alonso GordoaJaime R MerchanEric WinquistPablo MarotoJeffrey C GohMiso KimHoward GurneyVijay PatelAvivit PeerGiuseppe ProcopioToshio TakagiBohuslav MelicharFrederic RollandUgo De GiorgiShirley WongJens BedkeManuela SchmidingerCorina E DutcusAlan D SmithLea DuttaKalgi ModyRodolfo F PeriniDongyuan XingToni K Choueirinull nullPublished in: The New England journal of medicine (2021)
Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).